Jean‐Baptiste Bachet
Centre National de la Recherche Scientifique(FR)Inserm(FR)Université Paris Cité(FR)Université Paris-Saclay(FR)Sorbonne Université(FR)Centre Hospitalier Universitaire de Besançon(FR)Centre de Recherche des Cordeliers(FR)Assistance Publique – Hôpitaux de Paris(FR)Assistance Publique – Hôpitaux de Paris(FR)Normandie Université(FR)Pitié-Salpêtrière Hospital(FR)Advocate Illinois Masonic Medical Center(US)Université Marie et Louis Pasteur(FR)Université de Rouen Normandie(FR)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Gastric Cancer Management and Outcomes, Genetic factors in colorectal cancer
Most-Cited Works
- → FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer(2011)7,636 cited
- → FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer(2018)2,781 cited
- → KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer(2006)2,215 cited
- → KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab(2008)1,450 cited
- → Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial(2021)1,198 cited
- → Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer